ComplicationTumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma: Recurrence Pathway and Prognostic Factors
Section snippets
Study Time and Patients
From June 1989 to December 2003, with follow-up finished in September 2004 (mean follow up of 44.2 ± 41.7 months), we performed 961 OLTs including 9.8% in patients with HCC (n = 95). The male/female ratio was 74 (72.9%) to 21 (22.1%) with an overall mean age of 54.7 ± 8.7 years (range 15 to 70).
Functional Status and Preoperative Variables
Most patients were Child B (45.1 %, n = 41) or C (36.3%, n = 33). Preoperative transarterial chemoembolization was performed in 31 patients (33.7%) while on the waiting list. The mean alpha fetoprotein
Long-Term Survival
At the end of the study 56 of the 87 patients were alive (64.4%) with 1-, 3-, and 5-year actuarial survivals of 85%, 68.7%, and 60.2%, respectively, and a mean survival time of 122.1 ± 13.6 months. The 1-, 3-, and 5-year disease-free survivals (DFS) were 81%, 65%, and 57%, respectively with a mean DFS time of 114 ± 14.2 months.
During the follow-up the main cause of mortality was tumor recurrence (35.5%) and medical causes (29%). Six patients (19.4%) died due to liver disease recurrence and 5
Discussion
OLT is the management of choice for HCC and liver cirrhosis with good long-term outcomes longer survivals and lower recurrence incidences than liver resection especially with the application of Milan criteria: namely, a solitary tumor below 5 cm or no more than three nodules no larger than 3 cm3. With the application of these selection criteria, the recurrence incidence has decreased to 10% to 20%.1, 2, 3, 4 In this series, we observed a recurrence incidence of 15.8%, but it was an historical
References (16)
- et al.
Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry
Liver Transpl
(2002) - et al.
Vascular invasión and hitopahologic gradin determine outcome alter liver transplantation for hepatocellular carcinoma in cirrhosis
Hepatology
(2001) - et al.
Selection criteria for liver transplantation in early-stage hepatocellular carcinoma and cirrosis: results of a multicenter study
Liver Transpl
(2001) - et al.
Is transarterial chemoembolization necessry before liver transplantation for hepatocellular carcinoma
Am J Surg
(2005) - et al.
Liver transplantation for hepatocellular carcinoma
Ann Surg
(2001) - et al.
Hepatocellular cancer in liver transplantation
J Hepatobiliary Pancreat Surg
(2001) - et al.
Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrosis
N Engl J Med
(1996) - et al.
Liver transplantation for hepatocellular carcinoma: our experience from 1986
Transplant Proce
(2003)
Cited by (48)
A Step Closer to Personalized Treatment of Hepatocellular Carcinoma
2023, Academic RadiologyPrediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging
2023, Academic RadiologyCitation Excerpt :Therefore, identifying aggressive pathological features is of great significance in predicting HCC prognosis and treatment decisions. It is known that high pathologic grade in HCCs is closely related to aggressive tumor behavior and recurrence after surgery (3–5). According to one study, the five tumor-specific survival rates for high- and low-grade HCCs without vascular tumor thrombus were 18% and 81%, respectively (6).
Small hepatocellular carcinoma: using MRI to predict histological grade and Ki-67 expression
2019, Clinical RadiologyCitation Excerpt :Although small HCCs usually have better outcomes than larger HCCs, a subset of small HCCs have been identified as more aggressive, with poorer clinical prognosis. Investigators have reported that the histological grade of HCCs is a valuable prognostic factor; higher histological grades indicate worse survival probability.9,10 The nuclear protein, Ki-67, is associated with cell proliferative activity, which may be an indicator of tumour aggressiveness, and is expressed in all phases of the cell cycle except G0, with particularly high expression observed in the G2/M phase.11
MiR-503 regulates metastatic function through Rho guanine nucleotide exchanger factor 19 in hepatocellular carcinoma
2014, Journal of Surgical Research